[Federal Register Volume 84, Number 168 (Thursday, August 29, 2019)]
[Notices]
[Page 45480]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-18593]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary


Uniform Formulary Beneficiary Advisory Panel; Notice of Federal 
Advisory Committee Meeting

AGENCY: Under Secretary of Defense for Personnel and Readiness, 
Department of Defense (DoD).

ACTION: Notice of Federal Advisory Committee meeting.

-----------------------------------------------------------------------

SUMMARY: The Department of Defense (DoD) is publishing this notice to 
announce that the following Federal Advisory Committee meeting of the 
Uniform Formulary Beneficiary Advisory Panel will take place.

DATES:  Open to the public Wednesday, September 25, 2019, from 9:00 
a.m. to 12:00 p.m.

ADDRESSES: The address of the open meeting is the Naval Heritage Center 
Theater, 701 Pennsylvania Avenue NW, Washington, DC 20004. FOR

FOR FURTHER INFORMATION CONTACT:  Colonel Paul J. Hoerner, USAF, 703-
681-2890 (Voice), [email protected] (Email). Mailing 
address is 7700 Arlington Boulevard, Suite 5101, Falls Church, VA 
22042-5101. Website: https://health.mil/bap. The most up-to-date 
changes to the meeting agenda can be found on the website.

SUPPLEMENTARY INFORMATION: This meeting is being held under the 
provisions of the Federal Advisory Committee Act (FACA) of 1972 (5 
U.S.C., Appendix, as amended), the Government in the Sunshine Act of 
1976 (5 U.S.C. 552b, as amended), and 41 Code of Federal Regulations 
(CFR) 102-3.140 and 102-3.150. The Panel will review and comment on 
recommendations made to the Director of the Defense Health Agency, by 
the Pharmacy and Therapeutics Committee, regarding the Uniform 
Formulary.
    Purpose of the Meeting: The DoD is publishing this notice to 
announce that the following Federal Advisory Committee meeting of the 
Uniform Formulary Beneficiary Advisory Panel will take place.

Agenda

1. Sign-In
2. Welcome and Opening Remarks
3. Scheduled Therapeutic Class Reviews (Comments will follow each 
agenda item)
    a. Multiple Sclerosis Agents--Interferon
    b. Multiple Sclerosis Agents--Methyl Fumarate
    c. Corticosteroids--Immune Modulators--High Potency
4. Newly Approved Drugs Review
5. Pertinent Utilization Management Issues
6. Panel Discussions and Vote

    Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and 
41 CFR 102-3.140 through 102-3.165, and the availability of space, this 
meeting is open to the public. Seating is limited and will be provided 
only to the first 220 people signing-in. All persons must sign-in 
legibly.
    Written Statements: Pursuant to 41 CFR 102-3.140, the public or 
interested organizations may submit written statements to the 
membership of the Panel about its mission and/or the agenda to be 
addressed in this public meeting. Written statements should be 
submitted to the Panel's Designated Federal Officer (DFO).The DFO's 
contact information can be obtained previously in this notice. Written 
comments or statements must be received by the committee DFO at least 
five (5) business days prior to the meeting so that they may be made 
available to the Panel for its consideration prior to the meeting. The 
DFO will review all submitted written statements and provide copies to 
all the committee members.

    Dated: August 23, 2019.
Aaron T. Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2019-18593 Filed 8-28-19; 8:45 am]
 BILLING CODE 5001-06-P